Core Viewpoint - Moderna's stock has experienced a significant decline of 48% this year, but a rebound is anticipated following a strong Q3 performance, with revenue of $1.86 billion and adjusted earnings of $0.03 per share, surpassing consensus estimates [1] Group 1: Financial Performance - The company reported a revenue of $1.86 billion in Q3, exceeding the consensus estimate of $1.25 billion [1] - Adjusted earnings were $0.03 per share, compared to a consensus loss estimate of $1.90 per share [1] - Revenue for 2023 is projected to decline by 64% year-over-year to $6.8 billion, with expectations of further decline to approximately $3.5 billion in 2024 [1] Group 2: Product Pipeline and Innovations - Moderna has a robust pipeline with around 45 products in development, with nearly 25% expected to be commercialized in the next three to four years [4] - The new RSV vaccine is anticipated to gain traction due to its advantages, including easier storage and administration, and no reported cases of Guillain-Barré syndrome [2] - Recent clinical trials for the skin cancer vaccine show promising results, with a 44% reduction in recurrence or death compared to Merck's Keytruda alone [3] Group 3: Cost Management and Financial Health - The company has implemented cost-cutting initiatives aimed at saving $1.1 billion over the next three years, which is expected to enhance profitability [4] - Moderna holds $9.2 billion in cash, providing potential for acquisitions in the biotech sector [4] Group 4: Market Position and Analyst Outlook - Despite recent volatility, with annual returns of 143% in 2021, -29% in 2022, and -45% in 2023, analysts suggest that Moderna's stock is undervalued at around $50, with an average price estimate of $91 indicating an 80% upside [5][6] - The stock's performance has been more volatile compared to the S&P 500, raising questions about its future performance in the current macroeconomic environment [5][6]

Core Viewpoint - Moderna Inc reported better-than-expected third-quarter sales, with revenue of $1.83 billion, surpassing the consensus estimate of $1.25 billion, attributed to higher U.S. sales following the earlier launch of the updated COVID-19 vaccine [1][2]. Financial Performance - Third-quarter revenue was $1.83 billion, unchanged from the previous year, but exceeded expectations [1]. - Earnings per share was $0.03, a significant improvement from a loss of $(9.53) in the same quarter last year, compared to a consensus loss of $(1.90) [3]. Product Sales - Spikevax sales in the third quarter reached $1.8 billion, with $1.2 billion from U.S. sales and $0.6 billion from international sales [2]. - mRESVIA (RSV vaccine) sales were reported at $10 million, lower than anticipated due to late approval and recommendation [4]. Future Guidance - The company reiterated its expected net product sales for 2024 from its respiratory franchise to be between $3.0 billion and $3.5 billion [5]. - Cost of sales is expected to be 40-45% of product sales, with R&D expenses anticipated to be $4.6 billion to $4.7 billion [5]. - Moderna plans to file for approval of its next-generation COVID-19 vaccine and RSV vaccine in 2024 for high-risk adults aged 18-59 [5]. Market Reaction - MRNA stock increased by 7.04% to $55.46 during the premarket session following the earnings report [6].

Financial Performance - Moderna reported Q3 2024 revenue of $1.9 billion[6] - Net income for Q3 2024 was $13 million[6] - Cash and investments totaled $9.2 billion as of September 30, 2024, a decrease of $1.6 billion (15%) compared to June 30, 2024[6, 26] - Q3 2024 product sales reached $1.8 billion, with a year-to-date total of $2.2 billion[24] - The company expects $0.8 - $1.3 billion in product sales for Q4 2024 and reiterates expected 2024 product sales of $30 - $3.5 billion[24] - Operating expenses decreased by $1.9 billion (50%) from Q3 2023 to Q3 2024[25] COVID-19 Vaccine - Moderna's COVID vaccine approval was 19 days earlier in 2024 compared to 2023[8] - The company shipped 2x doses into the channel in the first week post-approval in 2024 vs 2023[8] - Moderna holds a 40% market share in the retail channel for the COVID vaccine season to date[9] RSV Vaccine - mRESVIA sales for Q3 2024 were $10 million[17] - The company anticipates a broader mRESVIA RSV label to include the 18-59 high-risk population[17] Pipeline and Future Outlook - Moderna intends to file for several respiratory vaccines in 2024, including next-generation COVID, RSV (18-59 HR), and combination Flu + COVID[32, 47] - The company aims for 10 product approvals over the next three years to drive sales growth[44, 47] - Moderna plans to reduce annual R&D expense by $1.1 billion starting in 2027, from a projected $4.8 billion for 2024 to $3.6-3.8 billion[44, 48]

Moderna (MRNA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $1.89 per share. This compares to loss of $1.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 101.59%. A quarter ago, it was expected that this biotechnology company would post a loss of $3.47 per share when it actually produced a loss of $3.33, delivering a surprise of 4.03%.Over the last four quarters, the ...

Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected. The biotech company posted a net income of $13 million, or 3 cents per share, for the third quarter. That compares with a net loss of $3.63 billion, or $9.53 cents per share, reported for the year-ago period.Moderna is slashing expenses, with a recently announced goal of achieving $1.1 billion in savings by 2027 ...

Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion for the quarter, compared to $1.83 billion a year earlier, according to data from Benzinga Pro.On Oct. 28, On Monday, Merck & Co Inc MRK and Moderna announced the initiation of INTerpath-009, a pi ...

Moderna (MRNA) is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.Estimates for Moderna’s 2024 loss per share have increased from $9.52 to $9.88 in the past 60 days. During the same period, estimates for 2025 loss per share have risen from $7.37 to $8.59. Image Source: Zacks Investment Re ...

Company Performance - Moderna's stock closed at $55.22, reflecting a +0.77% change, outperforming the S&P 500's gain of 0.16% on the same day [1] - Over the past month, Moderna's shares have declined by 18%, which is significantly worse than the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67% [1] Upcoming Earnings - Moderna is set to release its earnings report on November 7, 2024, with projected earnings of -$1.91 per share, indicating a year-over-year decline of 37.41% [2] - The Zacks Consensus Estimate for revenue is $1.25 billion, down 31.71% from the previous year [2] Full-Year Estimates - The full-year Zacks Consensus Estimates for Moderna indicate earnings of -$9.88 per share and revenue of $3.2 billion, representing year-over-year changes of +19.87% for earnings and -53.33% for revenue [3] Analyst Estimates - Recent modifications to analyst estimates for Moderna reflect evolving short-term business trends, with positive revisions seen as a favorable sign for the company's outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Moderna at 3 (Hold) [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Moderna, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have lost significantly in the past couple of years due to declining sales amid low demand for the vaccine. In the past month, MRNA stock fell more than 20% after management provided an update on its business outlook for the next four years. It also announced plans to slash its research and development (R&D) budget during this period. In the past month, the stock has underperformed the industry's 2.3% ...

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA therapeutics market size has grown steadily in recent years. It will grow from $33.5 billion in 2023 to $34.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $40.69 billion in 2028 at a compound annual growth rate (CAGR) of 4%. During ...